Despite its potential, targeting CXCL12 presents several challenges. The redundancy and compensatory mechanisms within the chemokine network can undermine the effectiveness of CXCL12 inhibition. Moreover, systemic blockade of CXCL12/CXCR4 can lead to adverse effects due to its involvement in normal physiological processes. Therefore, achieving specificity and minimizing side effects are crucial in the development of CXCL12-targeted therapies.
